Results 11 to 20 of about 961,893 (364)
Physiological Actions of Fibroblast Growth Factor-23 [PDF]
Frontiers in Endocrinology, 2018 Fibroblast growth factor-23 (FGF23) is a bone-derived hormone suppressing phosphate reabsorption and vitamin D hormone synthesis in the kidney. At physiological concentrations of the hormone, the endocrine actions of FGF23 in the kidney are αKlotho-dependent, because high-affinity binding of FGF23 to FGF receptors requires the presence of the co ...
Reinhold G. Erben
openaire +4 more sources
Effects of Single Vitamin D₃ Injection (200,000 Units) on Serum Fibroblast Growth Factor 23 and Sclerostin Levels in Subjects with Vitamin D Deficiency [PDF]
Endocrinology and Metabolism, 2017 Background: Vitamin D deficiency remains common in all age groups and affects skeletal and non-skeletal health. Fibroblast growth factor 23 is a bone-derived hormone that regulates phosphate and 1,25-dihydroxyvitamin D homeostasis as a counter regulatory
박혜선, 서다혜, 임승길
core +3 more sources
Fibroblast Growth Factor-23—A Potential Uremic Toxin [PDF]
Toxins, 2016 Fibroblast growth factor-23 (FGF23) is a circulating member of the FGF family produced mainly by the osteocytes and osteoblasts that can act as a hormone. The main action of FGF23 is to lower phosphatemia via the reduction of urinary phosphate reabsorption and the decrease of 1,25(OH)2-D generation in the kidney. In the course of chronic kidney disease
Piotr Kuczera +2 more
openaire +5 more sources
A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway [PDF]
Kidney International Reports, 2017 Phosphate homeostasis is a complex process involving communication among bones, kidneys, and other organ systems.1, 2 This is tightly regulated through parathyroid hormone (PTH) and bone-derived fibroblast growth factor 23 (FGF23).1, 2, 3 Disruption of either pathway has been associated with a number of disorders resulting in hypo- or hyperphosphatemia.
Matthew G. Sampson +6 more
openaire +4 more sources
Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients [PDF]
, 2008 Circulating fibroblast growth factor 23 (FGF23) increases renal phosphate excretion, decreases bone mineralization and is markedly increased in hemodialysis patients. Bone cells express fibroblast growth receptor 1, suggesting that FGF23 could alter bone
de Vernejoul, M.C. +4 more
core +3 more sources
Indian Journal of Endocrinology and Metabolism, 2011 Introduction: Secondary hyperparathyroidism (SHPT) is an insidious disease that develops early in the course of chronic kidney disease (CKD) and increases in severity as the glomerular filtration rate deteriorates.
Hamdy Sliem +3 more
doaj +2 more sources
The Role of Fibroblast Growth Factor-23 in Cardiorenal Syndrome [PDF]
Nephron Clinical Practice, 2013 Abnormalities in chronic kidney disease-related bone and mineral metabolism (CKD-MBD) have emerged as novel risk factors in excess cardiovascular mortality in patients with CKD and end-stage renal disease (ESRD). The pathophysiological links between CKD-MBD and adverse cardiovascular events in this patient population are unclear.
Leigh Quarles, Csaba P. Kovesdy
openaire +4 more sources
Frontiers in Medicine, 2023 IntroductionA negative association between C-terminal fibroblast growth factor 23 (cFGF23) and hemoglobin (Hb) levels has been reported in patients with predialysis chronic kidney disease.
Yu-Wei Fang +9 more
doaj +1 more source
Prognostic Importance of Fibroblast Growth Factor-23 in Dialysis Patients [PDF]
International Journal of Nephrology, 2014 Introduction. In this study, we aimed to demonstrate the correlation of FGF-23 levels with bone-mineral metabolism, anemia, and the treatment in dialysis patients. Methods.
Nilgül Akalin +5 more
core +2 more sources
Tumor-induced osteomalacia: Easing the diagnosis with fibroblast growth factor 23
APIK Journal of Internal Medicine, 2022 Tumor-induced osteomalacia (TIO), is a rare paraneoplastic syndrome resulting in bone pain, muscle weakness, and recurrent fractures. Hypophosphatemia, hyperphosphaturia, low 1, 25 dihydroxyVitamin D, and normal serum calcium are noted.
Mala Dharmalingam, Lohit Kumbar
doaj +1 more source